WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
maximize
Machine translation
1. (US20140045741) Method Of Treating An Ocular Disease And Compositions Effective For Treating An Ocular Disease
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

Claims

1. A method for treating an ocular disease in a human subject in need thereof by increasing the bioavailability of a drug in the subject's eye, the method comprising applying a therapeutically effective amount of a drug and an efflux transporter inhibitor, the amount of efflux transporter inhibitor applied in an amount effective to reduce the efflux of the drug through the subject's cornea.
2. The method according to claim 1, wherein the drug and efflux transporter inhibitor are topically applied to the subject's eye.
3. The method according to claim 1, wherein the efflux transporter inhibitor is effective to reduce the efflux of the drug through at least one efflux transporter selected from the group consisting of P-glycoprotein (Pgp), breast cancer resistant protein (BCRP), and multidrug resistant associated protein 1-9 (MRP1-9).
4. The method according to claim 1, wherein the drug is effective to treat at least one of diabetic retinopathy, macular degeneration, endopthalmitis, glaucoma, cataracts, ocular herpes and ocular diseases which can be treated to effect new blood vessels in the eye through angiogenesis of new blood vessels.
5. The method according to claim 1, wherein the drug is at least one of antimicrobial, antibiotic, beta blocker, carbonic anhydrase inhibitor, prostaglandin analogue, miotic, and sympthaomimetic.
6. The method according to claim 1, wherein the ocular disease is endophthalmitis.
7. The method according to claim 1, wherein the efflux transporter inhibitor is at least one of bevacizumab, itraconazole, caroxyamidotriazole, TNP-470, CM101, IFN-α, IL-12, platelet factor-4, suramin, SU5416, thrombospondin, VEGFR antagonists, angiostatic, steroids+heparin, cartilage-derived Angiogenesis Inhibitory Factor, matrix metalloproteinase inhibitors, angiostatin, endostatin, 2-methoxyestradiol, tecogalan, tetrathiomolybdate, thalidomide, thrombospondin, prolactin, αvβ3 inhibitors, linomide, tasquinimod, and cyclosporine A.
8. The method according to claim 1, wherein the drug is at least one of timolol, levobunolol, betaxolol and carteolol, dorzolamide, brinzolamide, latanoprost, latanoprost plus, travoprost, bimatoprost, unoprostone, pilocarpine, dipivefrine and brimonidine.
9. The method according to claim 1, wherein the efflux transporter inhibitor and drug are administered to ocular tissue at substantially the same time.
10. A method for treating at least one of diabetic retinopathy, macular degeneration, endopthalmitis, glaucoma, cataracts, ocular herpes in a subject in need thereof by increasing the bioavailability of a drug in the subject's eye, the method comprising administering to the subject's eye an efflux transporter inhibitor and a therapeutically effective amount of a drug which is effective for the treatment of at least one of diabetic retinopathy, macular degeneration, endopthalmitis, glaucoma, cataracts, ocular herpes, the amount of efflux transporter inhibitor applied in an amount effective to reduce the efflux of the drug through the subject's eye tissue and increase the effectiveness of the drug by at least 100% when the drug is applied at the same dosage levels at the same rate to treat the same disease at the same disease stage.
11. The method according to claim 10, wherein the efflux transporter inhibitor is at least one of bevacizumab, itraconazole, caroxyamidotriazole, TNP-470, CM101, IFN-α, IL-12, platelet factor-4, suramin, SU5416, thrombospondin, VEGFR antagonists, angiostatic, steroids+heparin, cartilage-derived Angiogenesis Inhibitory Factor, matrix metalloproteinase inhibitors, angiostatin, endostatin, 2-methoxyestradiol, tecogalan, tetrathiomolybdate, thalidomide, thrombospondin, prolactin, αvβ3 inhibitors, linomide, tasquinimod, and cyclosporine A.
12. The method according to claim 10, wherein the efflux transporter inhibitor and drug are administered at substantially the same time.
13. The method according to claim 10, wherein the drug and efflux transporter inhibitor are topically applied to the subject's eye.
14. The method according to claim 10, wherein the efflux transporter inhibitor is effective to reduce the efflux of the drug through at least one efflux transporter selected from the group consisting of P-glycoprotein (Pgp), breast cancer resistant protein (BCRP), and multidrug resistant associated protein 1-9 (MRP1-9).
15. The method according to claim 10, wherein the drug is at least one of antimicrobial, antibiotic, beta blocker, carbonic anhydrase inhibitor, prostaglandin analogue, miotic, and sympthaomimetic.
16. The method according to claim 10, wherein the drug is at least one of timolol, levobunolol, betaxolol and carteolol; dorzolamide, brinzolamide, latanoprost, latanoprost plus, travoprost, bimatoprost, unoprostone, pilocarpine, dipivefrine and brimonidine.
17. A composition for the treatment of an ocular disease in a subject, the composition comprising:
an ocular drug selected from the group consisting of antimicrobial, antibiotic, beta blocker, carbonic anhydrase inhibitor, prostaglandin analogue, miotic, and sympthaomimetic; and
an efflux transporter inhibitor is at least one bevacizumab, itraconazole, caroxyamidotriazole, TNP-470, CM101, IFN-α, IL-12, platelet factor-4, suramin, SU5416, thrombospondin, VEGFR antagonists, angiostatic, steroids+heparin, cartilage-derived Angiogenesis Inhibitory Factor, matrix metalloproteinase inhibitors, angiostatin, endostatin, 2-methoxyestradiol, tecogalan, tetrathiomolybdate, thalidomide, thrombospondin, prolactin, αvβ3 inhibitors, linomide, tasquinimod, and cyclosporine A,
the amount of efflux transporter inhibitor in an amount effective to reduce the efflux of the drug through the subject's eye tissue and increase the effectiveness of the drug by at least 100% when the drug is applied at the same dosage levels at the same rate to treat the same disease at the same disease stage, and the amount of drug effective to reduce or ameliorate at least one symptom of the ocular disease.
18. The composition according to claim 17, wherein the drug is at least one of beta blocker, carbonic anhydrase inhibitor, prostaglandin analogue, miotic, and sympthaomimetic and the efflux transporter inhibitor is at least one of bevacizumab, itraconazole, caroxyamidotriazole, TNP-470, CM101, IFN-α, IL-12, platelet factor-4, suramin, SU5416, thrombospondin, VEGFR antagonists, angiostatic, steroids+heparin, cartilage-derived Angiogenesis Inhibitory Factor, matrix metalloproteinase inhibitors, angiostatin, endostatin, 2-methoxyestradiol, tecogalan, tetrathiomolybdate, thalidomide, thrombospondin, prolactin, αvβ3 inhibitors, linomide, tasquinimod, and cyclosporine A.